The goal of the Developmental Research Program in the Mayo Clinic SPORE in Ovarian Cancer is to support innovative, scientifically sound research projects from which findings can be translated into clinically relevant intervenfions that will reduce the burden of ovarian cancer. The Developmental Research Program will 1) foster innovafive laboratory, populafion, and clinical study proposals that have strong translafional potenfial;2) encourage and support interdisciplinary collaboration in translational research in ovarian cancer; and 3) generate new hypotheses that can be tested in larger scale research projects or clinical trials in ovarian cancer. The Developmental Research Program will provide $200,000 annually ($100,000 from the SPORE and a matching $100,000 from Mayo) to support four meritorious projects each year. Depending on the progress on a given project, there will be the possibility of a second year of support. The Developmental Research Program will ufilize a defined process to call for applicafions on an annual basis and to review submissions, ufilizing the expertise of the Internal Scientific Advisory Committee and other experienced investigators as needed. Criteria for selection will include: the likelihood that the work will impact major challenges in ovarian cancer, scientific merit, originality, translafional potential, quallficafions of the key personnel, and interactivity. It is anticipated that support of pilot projects through this program will generate new hypotheses that can be addressed in exisfing SPORE-sponsored projects or through peer-reviewed external grant support. Brief descriptions of several potenfial developmental research projects are included to demonstrate the depth and breadth of ongoing research in ovarian cancer at Mayo Clinic

Public Health Relevance

The Developmental Research Program will support studies with high potenfial to impact ovarian cancer treatment and outcome. Four projects that encourage collaborations and generate new ideas to be tested will be supported each year.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA136393-05
Application #
8547774
Study Section
Special Emphasis Panel (ZCA1-RPRB-M)
Project Start
Project End
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
5
Fiscal Year
2013
Total Cost
$148,656
Indirect Cost
$55,156
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Karami, Sara; Han, Younghun; Pande, Mala et al. (2016) Telomere structure and maintenance gene variants and risk of five cancer types. Int J Cancer 139:2655-2670
Clyde, Merlise A; Palmieri Weber, Rachel; Iversen, Edwin S et al. (2016) Risk Prediction for Epithelial Ovarian Cancer in 11 United States-Based Case-Control Studies: Incorporation of Epidemiologic Risk Factors and 17 Confirmed Genetic Loci. Am J Epidemiol 184:579-589
Radecki Breitkopf, Carmen; Ridgeway, Jennifer L; Asiedu, Gladys B et al. (2016) Ovarian cancer patients' and their family members' perspectives on novel vaccine and virotherapy trials. Clin Trials 13:660-664
Ezewuiro, Obiageli; Grushko, Tatyana A; Kocherginsky, Masha et al. (2016) Association of Metformin Use with Outcomes in Advanced Endometrial Cancer Treated with Chemotherapy. PLoS One 11:e0147145
Li, Zheng; Block, Matthew S; Vierkant, Robert A et al. (2016) The inflammatory microenvironment in epithelial ovarian cancer: a role for TLR4 and MyD88 and related proteins. Tumour Biol 37:13279-13286
Pharoah, Paul D P; Song, Honglin; Dicks, Ed et al. (2016) PPM1D Mosaic Truncating Variants in Ovarian Cancer Cases May Be Treatment-Related Somatic Mutations. J Natl Cancer Inst 108:
(2016) Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. Nat Commun 7:12675
Karyampudi, Lavakumar; Lamichhane, Purushottam; Krempski, James et al. (2016) PD-1 Blunts the Function of Ovarian Tumor-Infiltrating Dendritic Cells by Inactivating NF-κB. Cancer Res 76:239-50
French, Juliet D; Johnatty, Sharon E; Lu, Yi et al. (2016) Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer. Oncotarget 7:6353-68
Harris, Faye R; Kovtun, Irina V; Smadbeck, James et al. (2016) Quantification of Somatic Chromosomal Rearrangements in Circulating Cell-Free DNA from Ovarian Cancers. Sci Rep 6:29831

Showing the most recent 10 out of 225 publications